Company in brief

Company in brief

Oncopeptides is a rapidly growing biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is science driven and is committed to bringing innovation to patients with an unmet need and improving patient lives.

Commercial launch

On February 26th PEPAXTO (melphalan flufenamide) in combination with dexamethason was granted accelerated approval by the U.S. Food and Drug Administration, FDA, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD38-directed monoclonal antibody. Following the approval PEPAXTO has been included in the new Multiple Myeloma Clinical Practice Guidelines of the National Comprehensive Cancer Network® (NCCN) in Oncology, in the US.

Evolving PDC-platform

Melflufen is the first drug candidate coming out of the company´s proprietary Peptide Drug Conjugate platform, PDC. Oncopeptides is developing several new compounds based on the PDC platform. The second compound from the PDC platform, OPD5, is ready to enter clinical development.

Oncopeptides has a facility for pre-clinical drug development in Solna, Sweden, which provides adequate resources to further expand the development of the PDC-platform and generate new drug candidates.

Oncopeptides on Nasdaq February 2017

Footprint in leading biotech hubs

The global headquarters is in Stockholm, Sweden, and the U.S. headquarters in Waltham, Massachusetts, outside of Boston. In addition, the company has an office in Los Altos, California, outside of San Francisco. We also have a modern pre-clinical drug development facility in Solna, outside Stockholm, Sweden.

Oncopeptides AB (publ) has approximately 300 coworkers and is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO.

Journey of innovation

Oncopeptides was formed in 2000 to develop anti-cancer drugs based on research by some of Sweden's leading cancer researchers and cancer research institutions. 
Read more


Oncopeptides has been granted an accelerated approval of PEPAXTO (melphalan flufenamide) in the US, and submitted an application for conditional marketing authorization. The strategy going forward is to ensure a successful commercialization in the US and to develop the product for a potential broadening of the indication, marketing authorization and commercialization in other regions on our own or in collaboration with partners, our strategy is to commercialize melflufen in the US and Europe with our own organization.

Read more

Governance structure

Oncopeptides’ corporate governance has, prior to the listing on Nasdaq Stockholm, been governed by the Swedish Companies Act (Sw. aktiebolagslagen (2005:551)), the Swedish Annual Accounts Act (Sw. årsredovisningslagen (1995:1554)) and other applicable laws and regulations, the Company’s articles of association and internal policy documents.

Read more